Kazia Therapeutics executive reports option holdings
Kazia Therapeutics executive David Cain filed an initial ownership report showing he holds several stock option awards.
Rhea-AI Filing Summary
Kazia Therapeutics executive David Cain filed an initial ownership report showing he holds several stock option awards. These include options over 5,000 American Depositary Shares at an exercise price of $19.0000 and 100,000 ADS at $8.0000, plus options over 100,000 and 400,000 Ordinary Shares at exercise prices of $0.6651 and $0.1061. The options vest in scheduled annual or quarterly installments, contingent on his continued service, and expire between February 1, 2027 and July 22, 2027.
Positive
- None.
Negative
- None.
Insider Trade Summary
4 transactions reported
Mixed
4 txns
Insider
Cain David
Role
Director, CMC
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | American Depositary Share Option (Right to Buy) | -- | -- | -- |
| holding | American Depositary Share Option (Right to Buy) | -- | -- | -- |
| holding | Ordinary Shares Option (Right to Buy) | -- | -- | -- |
| holding | Ordinary Shares Option (Right to Buy) | -- | -- | -- |
Holdings After Transaction:
American Depositary Share Option (Right to Buy) — 105,000 contracts (Direct);
Ordinary Shares Option (Right to Buy) — 500,000 contracts (Direct)
Footnotes (7)
- F1. The American Depositary Shares ("ADSs") subject to the option ("ADS option") vest in equal quarterly installments over three years beginning on July 22, 2024, subject to the Reporting Person's continuous service relationship with the Issuer through each applicable vesting date. The ADS option was granted on July 22, 2024.
- F2. Each ADS option is convertible into ADSs upon exercise.
- F3. Each ADS may be represented by 500 ordinary shares of the Issuer, no par per share (the "Ordinary Shares"), at any time, upon the holder's election to surrender the ADSs and withdraw the respective number of Ordinary Shares. The ADSs have no expiration date.
- F4. The ADSs subject to the ADS option vest in three equal annual installments beginning on July 3, 2025, subject to the Reporting Person's continuous service relationship with the Issuer through each applicable vesting date. The ADS option was granted on July 3, 2025.
- F5. The Ordinary Shares subject to the option ("OS option") vest in four equal annual installments beginning on February 1, 2022, subject to the Reporting Person's continuous service relationship with the Issuer through each applicable vesting date. The OS option was granted on February 1, 2022.
- F6. The exercise price is reported in U.S. dollars and reflects the conversion from AUD to USD at an exchange rate of 0.7075 USD per 1.00 AUD as of March 18, 2026.
- F7. The Ordinary Shares subject to the OS option vest in two equal annual installments beginning on March 3, 2023, subject to the Reporting Person's continuous service relationship with the Issuer through each applicable vesting date. The OS option was granted on March 3, 2023.
Key Figures
ADS options at $19.00: 5,000 underlying ADS
ADS options at $8.00: 100,000 underlying ADS
Ordinary Share options at $0.6651: 100,000 underlying Ordinary Shares
+2 more
5 metrics
ADS options at $19.00
5,000 underlying ADS
Exercise price $19.0000, expiration July 22, 2027
ADS options at $8.00
100,000 underlying ADS
Exercise price $8.0000, expiration July 3, 2027
Ordinary Share options at $0.6651
100,000 underlying Ordinary Shares
Exercise price $0.6651, expiration February 1, 2027
Ordinary Share options at $0.1061
400,000 underlying Ordinary Shares
Exercise price $0.1061, expiration March 3, 2027
FX conversion rate
0.7075 USD per 1.00 AUD
Used to report exercise prices as of March 18, 2026
Key Terms
American Depositary Shares, ADS option, Ordinary Shares Option, exercise price, +1 more
5 terms
ADS option financial
"The American Depositary Shares ("ADSs") subject to the option ("ADS option") vest"
exercise price financial
"The exercise price is reported in U.S. dollars and reflects the conversion from AUD"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vest financial
"subject to the Reporting Person's continuous service relationship with the Issuer through each applicable vesting date"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does David Cain’s Form 3 for Kazia Therapeutics (KZIA) report?
The Form 3 reports David Cain’s existing stock option holdings in Kazia Therapeutics. It lists options over American Depositary Shares and Ordinary Shares with defined exercise prices, vesting schedules based on continued service, and expiration dates through 2027.
When do David Cain’s Kazia Therapeutics stock options expire?
The reported options expire between February 1, 2027 and July 22, 2027. Each grant has its own specific expiration date, after which any unexercised options would lapse if not exercised under their terms.
How were the exercise prices for Kazia Therapeutics options converted to U.S. dollars?
The filing states the exercise prices are reported in U.S. dollars based on converting from Australian dollars at an exchange rate of 0.7075 USD per 1.00 AUD as of March 18, 2026, aligning the option terms with U.S. currency reporting.
AI-generated analysis. How Rhea-AI works. Not financial advice.
